CD274 and B-cell chronic lymphocytic leukemia: For example, it was shown that in CLL patients ibrutinib can enhance the T cell repertoire diversity (37), improve antigen presentation and reduce PD1 and PDL1 expression (38) and improve T cell numbers and function (39).